[The efficacy of the Zirtek (cetirizine) preparation in chronic recurrent urticaria and seasonal allergic rhinitis].
Clinical trials of a new histamine H1-blocker of the III generation zyrtec (cetirizine) manufactured in Belgium (UCB) demonstrated its high efficacy in pollenosis and chronic idiopathic urticaria. The drug has the advantage of a rapid absorption (a marked antihistamine effect occurs 2 hours upon administration), the action duration (24 hours), convenient regimen (once a day), the absence of CNS effects such as sleepiness, ow attention, reduced memory and discoordinated movements.
Androsov
V N
VN
Belostotskaia
O I
OI
Il'ina
N I
NI
D000293:Adolescent; D000328:Adult; D017332:Cetirizine / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D013607:Tablets; D016593:Terfenadine / Q000627:therapeutic use; D014581:Urticaria / Q000188:drug therapy*
D013607:Tablets; D016593:Terfenadine; D017332:Cetirizine
Effektivnost' preparata "Zirtek" (cetirizine) pri khronicheskoĭ retsidiviruiushcheĭ krapivnitse i sezonnom allergicheskom rinite.